Uncategorized

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE announced that the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for VYVGART Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy.

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy Read More »

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment

MediThinQ, a pioneering Korean startup specialising in extended reality wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays.

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment Read More »

Scroll to Top